132 related articles for article (PubMed ID: 10327031)
1. A phase II study employing combination regimens containing KRN8602 in drug-resistant acute myeloid leukemia and acute lymphoblastic leukemia. KRN8602 Leukemia Study Group.
Kishimoto Y; Sampi K; Kuraishi Y; Takemoto Y; Okabe K; Tamura K; Mizoguchi H; Saito H; Masaoka T; Ogawa M
Anticancer Drugs; 1999 Mar; 10(3):267-73. PubMed ID: 10327031
[TBL] [Abstract][Full Text] [Related]
2. [Pilot late phase II study of KRN8602 (MX2), a novel anthracycline derivative, for acute leukemia--a dose finding study in combination].
Hiraoka A; Sampi K; Kuraishi Y; Takemoto Y; Okabe K; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1999 Jan; 26(1):93-9. PubMed ID: 9987504
[TBL] [Abstract][Full Text] [Related]
3. [Early phase II study of KRN8602 (MX2), a novel anthracycline derivative for acute leukemia].
Takemoto Y; Sampi K; Kuraishi Y; Toki H; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2243-8. PubMed ID: 9881081
[TBL] [Abstract][Full Text] [Related]
4. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
Takemoto Y; Sampi K; Kuraishi Y; Okabe K; Tamura K; Mizoguchi H; Saito H; Masaoka T; Ogawa M
Int J Hematol; 1999 Jul; 70(1):20-5. PubMed ID: 10446490
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
[TBL] [Abstract][Full Text] [Related]
6. [Phase II study of KRN8602 (MX2) for malignant lymphoma].
Okabe K; Sampi K; Kuraishi Y; Takemoto Y; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1998 Jun; 25(7):1001-6. PubMed ID: 9644314
[TBL] [Abstract][Full Text] [Related]
7. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
[TBL] [Abstract][Full Text] [Related]
9. Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine.
Raanani P; Shpilberg O; Gillis S; Avigdor A; Hardan I; Berkowicz M; Sofer O; Lossos I; Chetrit A; Ben-Yehuda D; Ben-Bassat I
Leuk Res; 1999 Aug; 23(8):695-700. PubMed ID: 10456666
[TBL] [Abstract][Full Text] [Related]
10. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M
J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091
[TBL] [Abstract][Full Text] [Related]
11. Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.
Paciucci PA; Cuttner J; Holland JF
Semin Oncol; 1984 Sep; 11(3 Suppl 1):36-40. PubMed ID: 6385264
[TBL] [Abstract][Full Text] [Related]
12. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
Yavuz S; Paydas S; Disel U; Sahin B
Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
[TBL] [Abstract][Full Text] [Related]
13. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.
Kern W; Aul C; Maschmeyer G; Schönrock-Nabulsi R; Ludwig WD; Bartholomäus A; Bettelheim P; Wörmann B; Büchner T; Hiddemann W
Leukemia; 1998 Jul; 12(7):1049-55. PubMed ID: 9665189
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of KRN8602, 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin hydrochloride, MX2 x HCl in patients with metastatic breast cancer.
Katsumata N; Watanabe T; Tominaga T; Ogawa M; Adachi I; Enomoto K; Kajiwara T; Kusama M; Yamada Y; Abe O
Cancer Chemother Pharmacol; 1999; 43(6):441-4. PubMed ID: 10321502
[TBL] [Abstract][Full Text] [Related]
15. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D
J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
Wiernik PH; Cassileth PA; Leong T; Hoagland HC; Bennett JM; Paietta E; Oken MM;
Leuk Lymphoma; 2003 Sep; 44(9):1515-21. PubMed ID: 14565653
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer.
Clarke K; Basser RL; Maher D; Morgan DJ; Cebon J; Fox RM; Hill JS; Alt C; Bartlett J; Geldard H; Kaye AH; Green MD
J Clin Oncol; 1998 Jun; 16(6):2181-7. PubMed ID: 9626219
[TBL] [Abstract][Full Text] [Related]
18. Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG).
Ohno R; Kobayashi T; Morishima Y; Hiraoka A; Imai K; Asoh N; Tsubaki K; Tomonaga M; Takahashi I; Kodera K
Leukemia; 1992; 6 Suppl 2():92-5. PubMed ID: 1578954
[TBL] [Abstract][Full Text] [Related]
19. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
[TBL] [Abstract][Full Text] [Related]
20. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]